MedPageToday -- ORLANDO -- A popular therapy for multiple myeloma was associated with an excess of new cancers in three different studies presented here. The overall number of secondary malignancies was relatively small -- 44 in more than 800 patients treated with lenalidomide (Revlimid) -- but the results consistently showed a cancer excess compared with patients who received comparator therapies, researchers reported at the American Society of Hematology meeting.
